SUBSCRIBE
SUBSCRIBE

Nektar Therapeutics

NEWS
Investor
Biotech Bay
3 Hot Cancer Immunotherapies Waiting To Blast Off in 2018
Immuno-oncology therapeutics have revolutionized certain types of cancer treatments, and they are, in many ways, as close to miracle cures as we’ve seen in decades.
December 22, 2017
 · 
2 min read
 · 
Mark Terry
Small Cambridge Biotech Warp Bio Scores $387M R&D
Business
Daichi Sankyo Abandons Deal With Nektar Therapeutics After Drug Tanks in Europe
Daiichi Sankyo informed Nektar that it was terminating a collaboration and licensing deal, effective Feb. 4, 2018.
December 13, 2017
 · 
3 min read
 · 
Mark Terry
3 Biotechs That Got Huge Boosts From Spark's FDA P
BioMidwest
3 Biotech Stocks That Exploded in 2017
Rick Duprey, writing for The Motley Fool, takes a look at three biotech stocks that have quadrupled this year.
December 5, 2017
 · 
2 min read
 · 
Mark Terry
Gemini Therapeutics Banks $42.5M to Bring Precisio
Biotech Bay
3 Biotechs That Have Investors Grinning at Thanksgiving Dinner This Year
Investors have had a decent year, but some have much to be grateful for this Thanksgiving.
November 21, 2017
 · 
3 min read
 · 
Mark Terry
Bay Area's Nektar Inks $400 Million+ Autoimmune Disease Pact With Eli Lilly
Business
Bay Area’s Nektar Inks $400 Million+ Autoimmune Disease Pact With Eli Lilly
July 24, 2017
 · 
3 min read
Bay Area's Nektar Inks $400 Million+ Autoimmune Disease Pact With Eli Lilly
Biotech Bay
Bay Area Nektar’ Comeback is Stalled as the EMA Rejects Breast Cancer Drug
July 21, 2017
 · 
2 min read
Biotech Bay
Nektar Therapeutics: A Sweet Or Sour Investment?
June 15, 2017
 · 
1 min read
Bay Area's Nektar Inks $400 Million+ Autoimmune Disease Pact With Eli Lilly
Drug Development
For Sale: Nektar Therapeutics Plans to License Hot New Opioid Drug
March 20, 2017
 · 
3 min read
Drug Development
Nektar Therapeutics To Present At Jefferies Autumn 2015 Global Healthcare Conference In London
November 17, 2015
 · 
2 min read
Load More
AWARDS
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Business
Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan
April 17, 2023
 · 
11 min read
Biotech Bay
Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank
March 11, 2023
 · 
1 min read
Business
Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
February 28, 2023
 · 
12 min read
Drug Development
Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus
February 23, 2023
 · 
10 min read
Biotech Bay
Nektar Therapeutics’ President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA
January 4, 2023
 · 
1 min read
Biotech Bay
Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
December 12, 2022
 · 
9 min read
Biotech Bay
Nektar Therapeutics to Host Investor & Analyst Event on December 12th
December 5, 2022
 · 
5 min read
Biotech Bay
Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10, 2022
 · 
9 min read
Biotech Bay
Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy
November 9, 2022
 · 
7 min read
Business
Nektar Therapeutics Reports Third Quarter 2022 Financial Results
November 3, 2022
 · 
14 min read
Load More